Bispecific monoclonal antibodiesMeSH concept

https://www.has-sante.fr/jcms/p_3505636/fr/rybrevant-amivantamab-cancer-bronchique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
carboplatin
amivantamab
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
EGFR Exon 20 Insertion Mutation
Pemetrexed
adult
package leaflet
summary of product characteristics
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
bronchial neoplasms
amivantamab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
drug approval
Elranatamab
Elranatamab
multiple myeloma
recurrence
Progressive Neoplastic Disease
Triple-Class Refractory Multiple Myeloma
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Recurrent Multiple Myeloma
antibodies, monoclonal
antibodies, monoclonal
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
injections, subcutaneous
bispecific monoclonal antibodies
bispecific monoclonal antibodies
Immune Effector Cell Associated Neurotoxicity Syndrome
Elranatamab
Cytokine Release Syndrome
continuity of patient care
relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
elranatamab

---
https://www.has-sante.fr/jcms/p_3476377/fr/lunsumio-mosunetuzumab-lymphome-folliculaire-lf
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
bispecific monoclonal antibodies
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
infusions, intravenous
adult
Antineoplastic Agents, Immunological
mosunetuzumab
evaluation of the transparency committee
Mosunetuzumab
lymphoma, follicular

---
https://www.has-sante.fr/jcms/p_3463441/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
teclistamab
evaluation of the transparency committee
multiple myeloma
Teclistamab

---
https://www.has-sante.fr/jcms/p_3453127/fr/epcoritamab-abbvie-epcoritamab-lymphome-diffus-a-grande-cellule-b
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Epcoritamab
bispecific monoclonal antibodies
adult
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
guidelines for drug use
epcoritamab

---
https://ansm.sante.fr/tableau-marr/epcoritamab
2023
false
false
false
France
French
risk management
bispecific monoclonal antibodies
Epcoritamab
patients guideline
Cytokine Release Syndrome
signs and symptoms
Immune Effector Cell Associated Neurotoxicity Syndrome
cell-associated neurotoxicity
drug information
epcoritamab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli
2022
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Teclistamab
Teclistamab
antibodies, monoclonal
antibodies, monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
teclistamab
injections, subcutaneous
drug interactions
pregnancy
breast feeding
Triple-Class Refractory Multiple Myeloma
recurrence
product surveillance, postmarketing
bispecific monoclonal antibodies
bispecific monoclonal antibodies
b-cell maturation antigen
CD3 Complex

---